Skip to content

Author

R. Boellaard

We have 4 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

18F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry.

Programmed death ligand 1 (PD-L1) immunohistochemistry, the current standard biomarker for predicting response to programmed death protein 1/PD-L1 checkpoint inhibitors in non-small cell lung cancer, has moderate predictive value among others because of tumor heterogeneity and limited biopsy representation, whereas PD-...

F. J. Borm, Jasper Smit, N. Gerards et al. · 0 citations
Open access Oct 2026

Post-acute sequelae of COVID-19 (PASC) are associated with distinct clinical phenotypes two years after SARS-CoV-2 infection: A data-driven approach

It is important to determine whether the persistent cognitive and fatigue complaints, as part of post-acute sequelae of COVID-19 (PASC), are associated with underlying patterns and specific symptoms clusters. Therefore, the aim of the present study was to investigate symptom clusters and clinical phenotypes in PASC. We...

S. Verfaillie, A. Verveen, D. Visser et al. · 0 citations
Open access Aug 2026

Diffuse glioma perfusion quantification with ASL and DSC: a head-to-head comparison with 15O-H2O PET

While neither ASL nor DSC is fully comparable to 15O-H2O PET in all tumors, ASL presents a viable non-invasive alternative to DSC for glioma imaging and the findings encourage future studies to investigate the extent to which the combination of ASL and DSC can measure complementary tumor hemodynamics.

J. Petr, N. Verburg, J. Kuijer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.